WO2020159169A3 - 당화된 ag85a 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법 - Google Patents

당화된 ag85a 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법 Download PDF

Info

Publication number
WO2020159169A3
WO2020159169A3 PCT/KR2020/001230 KR2020001230W WO2020159169A3 WO 2020159169 A3 WO2020159169 A3 WO 2020159169A3 KR 2020001230 W KR2020001230 W KR 2020001230W WO 2020159169 A3 WO2020159169 A3 WO 2020159169A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosylated
protein
vaccine composition
ag85a
ag85a protein
Prior art date
Application number
PCT/KR2020/001230
Other languages
English (en)
French (fr)
Other versions
WO2020159169A2 (ko
Inventor
이용직
손은주
신성재
김홍민
조관구
오명열
Original Assignee
주식회사 바이오앱
연세대학교 산학협력단
주식회사 큐라티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 바이오앱, 연세대학교 산학협력단, 주식회사 큐라티스 filed Critical 주식회사 바이오앱
Priority to JP2021543360A priority Critical patent/JP7233662B2/ja
Priority to EP20748794.3A priority patent/EP3919075A4/en
Priority to US17/426,275 priority patent/US20220088167A1/en
Priority to CN202080011317.9A priority patent/CN113365655A/zh
Publication of WO2020159169A2 publication Critical patent/WO2020159169A2/ko
Publication of WO2020159169A3 publication Critical patent/WO2020159169A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물, 상기 단백질의 제조를 위한 벡터, 상기 벡터를 이용한 형질전환체, 및 상기 형질전환체를 이용하여 당화된 Ag85A 단백질을 생산하는 방법 등에 관한 것으로, 본 발명의 당화된 Ag85A 단백질을 포함하는 백신 조성물은, 결핵 방어 효과에 중요한 IFN-γ, TNF-α 및 IL-2를 동시에 분비하는 다기능성 T세포 증가를 유도하는 효과가 있어 결핵 예방용 백신으로 유용하게 이용될 수 있으며, 나아가, 상기 당화된 Ag85A 단백질은 단백질 생산에 최적화된 벡터를 이용하여 식물체에서 효과적으로 발현되고 높은 수율로 분리될 수 있어 저렴한 비용으로 대량 생산이 가능하다.
PCT/KR2020/001230 2019-01-28 2020-01-23 당화된 ag85a 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법 WO2020159169A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021543360A JP7233662B2 (ja) 2019-01-28 2020-01-23 グリコシル化したａｇ８５ａタンパク質を含む結核予防用ワクチン組成物およびその製造方法
EP20748794.3A EP3919075A4 (en) 2019-01-28 2020-01-23 VACCINE COMPOSITION FOR THE PREVENTION OF TUBERCULOSIS WITH GLYCOSYLATED AG85A PROTEIN AND METHOD OF MANUFACTURE THEREOF
US17/426,275 US20220088167A1 (en) 2019-01-28 2020-01-23 Vaccine composition for preventing tuberculosis, comprising glycosylated ag85a protein and method for preparing same
CN202080011317.9A CN113365655A (zh) 2019-01-28 2020-01-23 包含糖基化ag85a蛋白的用于预防结核病的疫苗组合物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190010431A KR102317403B1 (ko) 2019-01-28 2019-01-28 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법
KR10-2019-0010431 2019-01-28

Publications (2)

Publication Number Publication Date
WO2020159169A2 WO2020159169A2 (ko) 2020-08-06
WO2020159169A3 true WO2020159169A3 (ko) 2020-10-15

Family

ID=71841615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/001230 WO2020159169A2 (ko) 2019-01-28 2020-01-23 당화된 ag85a 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법

Country Status (6)

Country Link
US (1) US20220088167A1 (ko)
EP (1) EP3919075A4 (ko)
JP (1) JP7233662B2 (ko)
KR (1) KR102317403B1 (ko)
CN (1) CN113365655A (ko)
WO (1) WO2020159169A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102557824B1 (ko) * 2020-08-18 2023-07-20 주식회사 바이오앱 식물 발현 재조합 지카바이러스 외피단백질을 포함하는 백신 조성물 및 이의 제조방법
KR102630105B1 (ko) * 2020-11-26 2024-01-29 전남대학교산학협력단 Cel12A 단백질을 포함하는 셀룰로오스 분해용 조성물 및 이의 제조방법
KR20230119865A (ko) * 2022-02-08 2023-08-16 연세대학교 산학협력단 당사슬이 절단된 신규 항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101845456A (zh) * 2010-03-31 2010-09-29 暨南大学 结核Ag85B基因的玉米表达载体及其应用
KR20110037880A (ko) * 2009-10-06 2011-04-13 헬릭스 주식회사 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법
KR101832019B1 (ko) * 2010-12-21 2018-02-23 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 백신으로서의 재조합 마이코박테리움
KR101848082B1 (ko) * 2017-05-11 2018-04-12 주식회사 바이오앱 셀룰로오즈 결합 도메인을 포함하는 재조합 벡터 및 상기 벡터를 사용하여 단백질을 분리정제하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288261B2 (en) * 2000-07-10 2007-10-30 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
KR100609813B1 (ko) * 2005-02-24 2006-08-08 학교법인연세대학교 결핵 예방 백신
CN101468201B (zh) * 2007-12-27 2012-09-05 上海万兴生物制药有限公司 一种结核分枝杆菌多价重组蛋白疫苗的制备
CN101969976A (zh) * 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
JP2013500329A (ja) * 2009-07-29 2013-01-07 ヘルムート アダム レフム ベルン ポリマー粒子およびその使用
EA038931B9 (ru) * 2014-11-20 2022-02-18 Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений
KR101579861B1 (ko) 2015-04-10 2015-12-23 연세대학교 산학협력단 Ｒｖ３１３１ 단백질을 포함하는 결핵 예방용 백신 조성물
JP2019021828A (ja) 2017-07-20 2019-02-07 株式会社Ｓｃｒｅｅｎホールディングス 熱処理装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110037880A (ko) * 2009-10-06 2011-04-13 헬릭스 주식회사 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법
CN101845456A (zh) * 2010-03-31 2010-09-29 暨南大学 结核Ag85B基因的玉米表达载体及其应用
KR101832019B1 (ko) * 2010-12-21 2018-02-23 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 백신으로서의 재조합 마이코박테리움
KR101848082B1 (ko) * 2017-05-11 2018-04-12 주식회사 바이오앱 셀룰로오즈 결합 도메인을 포함하는 재조합 벡터 및 상기 벡터를 사용하여 단백질을 분리정제하는 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GONZALEZ, PABLO A.: "Efficient production of glycosylated and non-glycosylated mycobacterium tuberculosis antigen 85B fused to PVX coat protein in Nicotiana benthamiana plants", AMERICAN JOURNAL OF BIOCHEMISTRY AND BIOTECHNOLOGY, 2018, pages 238 - 246, XP055747689 *

Also Published As

Publication number Publication date
JP7233662B2 (ja) 2023-03-07
JP2022518807A (ja) 2022-03-16
WO2020159169A2 (ko) 2020-08-06
KR102317403B1 (ko) 2021-10-29
EP3919075A2 (en) 2021-12-08
US20220088167A1 (en) 2022-03-24
CN113365655A (zh) 2021-09-07
EP3919075A4 (en) 2022-11-09
KR20200093723A (ko) 2020-08-06

Similar Documents

Publication Publication Date Title
WO2020159169A3 (ko) 당화된 ag85a 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법
WO2015048334A3 (en) Edible species nutritive polypeptides and methods of production and use thereof
WO2014153111A3 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
MX2016009072A (es) Fusion de antigenos micobacterianos heterooligomericos.
WO2015048339A3 (en) Compositions and formulations for non-human nutrition and methods of production and use thereof
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
EP3988115A3 (en) Rsv f protein compositions and methods for making same
SA517390134B1 (ar) مركبات ميوتين إنترلوكين-2 لتمديد خلايا تائية منظمة
MX2019000082A (es) Una novedosa tagatosa-6-fosfato fosfatasa termoestable y un procedimiento para producir tagatosa usando la misma.
SG10201901559SA (en) Retinal ganglion cells and progenitors thereof
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
WO2017048809A8 (en) Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
WO2016011179A3 (en) Methods of increasing crop yield under abiotic stress
WO2018097603A3 (ko) 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
EP4286524A3 (en) Fungal cell with improved protein production capacity
PH12017501856A1 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
WO2013021284A3 (en) Anti-il-6 vaccine composition
WO2020033970A3 (en) Composition for a molded body
BR112018002284A2 (pt) método de fermentação para produzir um bioproduto, levedura crabtree negativa geneticamente engenheirada e método para reduzir a produção de glicerol por uma levedura engenheirada
WO2018190677A3 (en) METHOD OF PURIFYING ANALOGUE ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY
WO2018055535A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
WO2016179086A3 (en) Chlamydomonas strains with chloroplast-expressed cry proteins for biological control of mosquitoes that transmit disease
WO2021016227A8 (en) Synthetic genetic elements for biomanufacture
WO2015048796A3 (en) Mosaic hiv envelope immunogenic polypeptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20748794

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021543360

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020748794

Country of ref document: EP

Effective date: 20210830